Aristides Capital LLC Takes $189,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Aristides Capital LLC purchased a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 32,500 shares of the company’s stock, valued at approximately $189,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in shares of Olema Pharmaceuticals by 52.1% in the fourth quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company’s stock valued at $8,839,000 after acquiring an additional 522,799 shares during the period. Schroder Investment Management Group boosted its holdings in Olema Pharmaceuticals by 548.7% in the 4th quarter. Schroder Investment Management Group now owns 533,111 shares of the company’s stock valued at $2,991,000 after purchasing an additional 450,924 shares during the period. Pier Capital LLC acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter worth approximately $1,588,000. Franklin Resources Inc. increased its holdings in shares of Olema Pharmaceuticals by 1,714.9% during the fourth quarter. Franklin Resources Inc. now owns 273,706 shares of the company’s stock worth $1,596,000 after purchasing an additional 258,625 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Olema Pharmaceuticals by 12.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,883,354 shares of the company’s stock valued at $10,980,000 after buying an additional 215,895 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their target price on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, March 28th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. Finally, Oppenheimer reiterated an “outperform” rating and set a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Insider Buying and Selling

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were acquired at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the transaction, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. This represents a 4.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 19.40% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals Trading Down 2.2 %

OLMA stock opened at $3.18 on Tuesday. The stock has a market capitalization of $217.30 million, a P/E ratio of -1.45 and a beta of 2.10. The firm has a 50-day moving average price of $4.69 and a 200-day moving average price of $7.63. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.12. As a group, equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.